Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer
Open Access
- 13 June 2006
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 94 (12), 1803-1808
- https://doi.org/10.1038/sj.bjc.6603196
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Synergistic effects of docetaxel and S‐1 by modulating the expression of metabolic enzymes of 5‐fluorouracil in human gastric cancer cell linesInternational Journal of Cancer, 2006
- Phase II Multi-Institutional Randomized Trial of Docetaxel Plus Cisplatin With or Without Fluorouracil in Patients With Untreated, Advanced Gastric, or Gastroesophageal AdenocarcinomaJournal of Clinical Oncology, 2005
- Current status and future prospects of chemotherapy for metastatic gastric cancer: a reviewGastric Cancer, 2005
- Cancer Statistics, 2005CA: A Cancer Journal for Clinicians, 2005
- Palliative chemotherapy for advanced gastric cancerAnnals of Oncology, 2004
- Docetaxel, 5-fluorouracil, and leucovorin as treatment for advanced gastric cancer: results of a phase II studyGastric Cancer, 2002
- Phase II Study of S-1, a Novel Oral Derivative of 5-Fluorouracil, in Advanced Gastric CancerOncology, 2000
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1M tegafur–0.4M gimestat–1M otastat potassium) in advanced gastric cancer patientsEuropean Journal Of Cancer, 1998
- An improved synthesis of the taxol side chain and of RP 56976The Journal of Organic Chemistry, 1990